2022 BioInfect Conference

2022 BioInfect Conference

Alderley Park Conference Centre
Wednesday 9th March 2022


Antimicrobial resistance is one of the biggest public health challenges of our time and fighting this serious threat is a priority that requires a collaborative approach across all sectors. BioInfect will look at the critical issues relating to the development of new anti-infectives, the endemic problem of resistance and the considerations for creating a truly global and effective response to antimicrobial resistance.

We are delighted that Dr John H. Rex, MD will give a keynote address at this years event

Antimicrobial resistance today
Antimicrobial resistance arises when the organisms that cause infection evolve ways to survive treatment. Once standard treatments are ineffective, it is easier for infections to persist and spread. These resistant organisms can be found in people, animals, food and the environment. The rise and spread of antimicrobial resistance are creating a new generation of ‘superbugs’ that cannot be treated with existing medicines. 

Drug-resistant bacteria infect over 50m people worldwide killing over 700,000 people each year. Without effective antibiotics, even minor surgery and routine operations could become high-risk procedures if serious infections can’t be treated.

2020 Attendees
In 2020 we welcomed delegates from Roche, Pfizer, Ineos Oxford Institute, TB Alliance, Infex Therapeutics, Evotec, Liverpool School of Tropical Medicine, Antibiotic Research UK, Medicines Discovery Catapult, Pro-Lab Diagnostics, NHS, BIVDA, University of Cambridge, Biotaspheric, Destiny Pharma, Alder Hey Children's NHS Foundation Trust, Cresset Discovery Services, NICE, Global AMR R&D Hub, Innovation Agency, Mutabilis, Vedanta Biosciences, AMR Action Fund, Knowledge Transfer Network, Apis Assay Technologies, Northumbria University, Withers & Rogers, BMG Labtech, University of Huddersfield, University of Manchester, AF ChemPharm, SRG, Sai Life Sciences, Durham University, University of Leeds, IN.PACT eK, Bio2Business, RSM, Melhor Consulting, Alderley Park Ltd and MFT.

Further details will be available shortly.

John H. Rex, MD

                                       Chief Medical Officer, F2G Ltd. · Operating Partner, Advent Life Sciences · Adjunct Professor of Medicine, McGovern Medical School

I am a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. My experience includes moving antifungal and antibacterial agents from preclinical development thru all development phases in the context of (a) academic positions (NIAID, University
of Texas-Houston), (b) VP-level roles at a pharmaceutical multinational (AstraZeneca), (c) board-level roles in in biotech companies (F2G, Ltd.; Adenium Biotech ApS), (d) Expert-in-Residence at Wellcome Trust, (e) Chief Strategy Officer for CARB-X, and (f) an Operating Partner role with Advent Life Sciences. The first 15 years of my career focused on medical mycology and spanned susceptibility testing methods, in vitro-in vivo translational studies, and clinical trials. More recently, my work has broadened to include advancing novel regulatory and reimbursement paradigms for antimicrobial agents, founding
of the New Drugs for Bad Bugs (ND4BB) program of Europe’s Innovative Medicines Initiative (IMI), and leadership of an antifungal-focused biotech company. 



Premium Member Delegate Pass

  • £99 + VAT

Member Delegate Pass

  • £150 + VAT

Non Member Delegate Pass

  • £295 + VAT

Premium Member Gold Exhibitor Package

  • £395 + VAT

Premium Member Silver Exhibitor Package

  • £325 + VAT

Member Gold Exhibitor Package

  • £495 + VAT

Member Silver Exhibitor Package

  • £395 + VAT

Non-Member Gold Exhibitor Package

  • £575 + VAT

Non-Member Silver Exhibitor Package

  • £495 + VAT




Alderley Park is a place where world leading science, innovation and stylish living come together to create a place like no other.

Part of Bruntwood SciTech, a 50:50 joint venture between leading property company Bruntwood and Legal and General, Alderley Park is currently undergoing £247m investment.  Home to the internationally-recognised Mereside bioscience campus, the Park offers more than 1m sq ft of high specification lab space, a range of scientific services and an accelerator delivering a comprehensive programme of business support for start-ups and scale-ups.  It is also home to a vibrant and fast growing community of over 60 established and 150 pre-start up companies.


Alderley Park
Congleton Road
Nether Alderley
SK10 4TG



Alderley Park is centrally located within easy reach of the M6 and M56 motorway networks. It is located just 18 miles away from Manchester city centre and 20 minutes from Manchester Airport which offers flights to 225 destinations around the world. The Park offers easy access to Manchester and the rest of the UK by train with three local stations (Alderley Edge, Wilmslow and Macclesfield) all within 15 minutes drive.